AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie Inc. is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting ...

The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...

Wednesday closed down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.38%, and the Nasdaq 100 Index ...

The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and ...

Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8 ...